Stock Events

Stock Events

Biophytis 

€0.016300
41
-€0.00-1.21% Friday 12:29

Statistics

Day High
0.0163
Day Low
0.016
52W High
0.0518
52W Low
0.0036
Volume
531
Avg. Volume
153,519
Mkt Cap
381,957.9
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11SepExpected
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-1.24
-0.89
-0.53
-0.17
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-10.38MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0D1W.LSE. It's not an investment recommendation.
TotalEnergies
8
TTE.PA
Axa
7
CS.PA
Air Liquide
6
AI.PA
Sanofi
6
SAN.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Biophytis' focus on rare diseases and aging-related diseases.
PTC Therapeutics
PTCT
Mkt Cap7.04B
PTC Therapeutics operates in the field of genetic disorders, including therapies for rare diseases, competing in the same space as Biophytis.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic diseases, aligning with Biophytis' focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, targeting genetic diseases and disorders, which overlaps with Biophytis' therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the genetic and rare disease space.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical focuses on developing treatments for rare and ultra-rare genetic diseases, sharing a target market with Biophytis.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing technology, targeting diseases with genetic causes, which puts it in competition with companies developing treatments for rare genetic disorders.
Novartis
NVS
Mkt Cap293.94B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for rare diseases, making it a competitor on a larger scale.

About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Show more...
CEO
Mr. Stanislas Veillet Ph.D.
Employees
19
Country
France
ISIN
FR001400OLP5

Listings

MU
DE
6XB.MU
STU
DE
6XB3.STU
PA
FR
BPYBS.PA
STU
DE
6XB.STU

0 Comments

Share your thoughts

FAQ

What is Biophytis stock price today?▼
The current price of 0D1W.LSE is €0.02 EUR — it has decreased by -1.21% in the past 24 hours. Watch Biophytis stock price performance more closely on the chart.
What is Biophytis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Biophytis stocks are traded under the ticker 0D1W.LSE.
What is Biophytis market cap?▼
Today Biophytis has the market capitalization of 381,957.9
When is the next Biophytis earnings date?▼
Biophytis is going to release the next earnings report on September 11, 2026.
What is Biophytis revenue for the last year?▼
Biophytis revenue for the last year amounts to 0 EUR.
What is Biophytis net income for the last year?▼
0D1W.LSE net income for the last year is -10.38M EUR.
How many employees does Biophytis have?▼
As of July 14, 2026, the company has 19 employees.
In which sector is Biophytis located?▼
Biophytis operates in the Manufacturing sector.
When did Biophytis complete a stock split?▼
The last stock split for Biophytis was on May 03, 2024 with a ratio of 1:400.
Where is Biophytis headquartered?▼
Biophytis is headquartered in Paris, France.